Although MAPK-targeted therapies (such as MEK inhibitors) have shown efficacy in melanoma and lung cancer, their application in KIRC is hindered by compensatory feedback loops and dose-limiting toxicity (76). This evidence concerns the gene MAP2K7 and lung carcinoma.